The aim of this trial is to demonstrate similarity in efficacy between ABP 938 8 mg and aflibercept (US) 8 mg by evaluating the change in best corrected visual acuity (BCVA) in participants with neovascular age-related macular degeneration (nAMD)
Men or women ≥ 50 years old, capable of giving signed informed consent
Active, treatment-naïve subfoveal CNV lesions secondary to nAMD including juxtafoveal lesions that affect the fovea as confirmed by SD-OCT and FA in the study eye (SE)
Total area of CNV (including both classic and occult components) > 50% of the total lesion area in the SE
The BCVA letter score ≥ 24 and ≤ 78 letters, in the SE
Total lesion size > 12 disc areas (30.5 mm2) including blood, scars, and neovascularization, in the study eye
Scar, fibrosis, or atrophy involving the central subfield in the study eye
Scar or fibrosis involving > 50% of the total lesion in the study eye
Presence of retinal pigment epithelium tears or rips involving the macula in the study eye